Drugs / Ontorpacept
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02890368 | Sep 2016 → Mar 2020 | breast carcinoma, cutaneous neuroendocrine carcinoma, melanoma, mycosis fungoides +2 | Pfizer | Terminated | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05507541 | Apr 2023 → Jul 2027 expected | ALK-positive large B-cell lymphoma, B-cell lymphoma, unclassifiable, with features intermediate between diffuse large b-cell lymphoma and classical Hodgkin lymphoma, T-cell/histiocyte rich large B cell lymphoma, diffuse large B-cell lymphoma with chronic inflammation +5 | Mayo Clinic | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04996004 | Jun 2021 → Dec 2023 | leiomyosarcoma | Pfizer | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ontorpacept | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05507541 ↗ |
| Known as | TTI-621 | “Ontorpacept (TTI-621) will be administered by intravenous infusion.” NCT04996004 ↗ |
| Action | Inhibit | “TTI-621 acts by binding human CD47 and preventing it from delivering an inhibitory "do not eat" (antiphagocytic) signal to macrophages.” NCT02890368 ↗ |
| Modality | Protein / enzyme biologic | “TTI-621 (SIRPα-IgG1 Fc) is a soluble recombinant fusion protein” NCT02890368 ↗ |
| Route | Other | “intratumoral injections” NCT02890368 ↗ |